NEO
NeoGenomics, Inc.11.67
-0.25-2.1%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
High-value shift crimps early volumes
Q&A elaborated NeoGenomics' exit of a high-volume, low-$200 AUP contract, intentionally crimping Q1/Q2 volumes sequentially while flipping growth to upper-single-digit AUP from lower-single-digit volumes. Management detailed RADAR ST execution: end-month launch focused on head/neck/breast, initial ENT sales team now, 25+ OSS by Q3 for new indications. Pharma services see 5-10% erosion, stabilizing 2027 via MRD. LIMS phased rollout aids H2 efficiencies; gross margins rise 100-120bps. Shift favors margins. Confident tone on 10% revenue guide; watch clinical volume rebound, LBX timing.
Key Stats
Market Cap
1.51BP/E (TTM)
-Basic EPS (TTM)
-0.89Dividend Yield
0%Recent Filings
10-K
FY2025 results
NeoGenomics posted FY2025 revenue of $727M, up 10.1% y/y, fueled by higher test volumes and a shift to higher-value assays, though Q4 specifics remain undisclosed in the 10-K. Gross margins slipped to 43.2% from 43.9% amid Pathline acquisition costs and elevated compensation, yet Adjusted EBITDA climbed 9.5% to $43M through efficiency gains. Q4 momentum showed in clinical services acceleration, but impairments hit $28M from InVisionFirst-Lung wind-down and Trapelo asset sale. Cash dropped to $160M post-2025 note repayment; $342M remains in 2028 notes. 2026 eyes MRD and therapy selection growth. Capacity constraints risk crimping quarterly volume ramps.
8-K
Q4 revenue hits $190M
NeoGenomics posted Q4 revenue up 11% to $190M and full-year up 10% to $727M, fueled by 23% NGS growth and higher-value tests, while resolving RaDaR ST patent litigation. Net loss narrowed to $10M in Q4 yet widened to $108M yearly amid impairments. Cash sits at $160M. Guidance eyes $793-801M revenue in 2026.
8-K
Preliminary revenue, CFO transition
NeoGenomics reported preliminary Q4 2025 revenue of ~$190M, up 11% year-over-year, and full-year revenue of $727M, up 10%. CFO Jeff Sherman transitions to EVP Finance on March 2, 2026, before retiring April 14; Abhishek Jain, ex-CareDx CFO, steps in as EVP Finance immediately and assumes CFO role March 2. Leadership shift aids audit completion. Results preliminary, subject to material change.
8-K
NeoGenomics appoints board veteran
NeoGenomics accepted Dr. Alison Hannah's board resignation effective December 31, 2025, and appointed diagnostics veteran Jack Kenny effective January 1, 2026, to fill the vacancy until the 2026 annual meeting. Kenny brings 30+ years leading lab services firms like Meridian Bioscience and Siemens. His expertise targets NGS and MRD growth. No related transactions disclosed.
10-Q
Q3 FY2025 results
NeoGenomics posted Q3 revenue of $187.8M, up 11.9% y/y from $167.8M, with gross margin slipping to 42.8% from 44.6% on higher compensation and supplies. Operating loss widened to $27.0M from $21.2M, hit by $7.1M Trapelo impairment; net loss reached $27.1M or $(0.21) per share versus $(0.14), EPS matching diluted shares of 128.4M. Pathline closed April 2025 for $8.5M (cash/contingent), adding $5.1M goodwill and $1.2M customer intangibles (7 years). Cash fell to $164.1M after repaying $201M 2025 notes, leaving $341.5M 2028 notes (0.25%, due 2028); OCF YTD turned positive at $3.9M. Patent suits linger.
IPO
Website
Employees
Sector
Industry
DGX
Quest Diagnostics Incorporated
178.66-5.45
FLGT
Fulgent Genetics, Inc.
27.16+0.24
GNTLF
GENETIC TECHNOLOGIES
1.00+0.00
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
NEOG
Neogen Corporation
7.04+0.19
PSNL
Personalis, Inc.
7.98-0.50
QGEN
Qiagen N.V.
45.01-0.43
TMO
Thermo Fisher Scientific Inc
570.16-5.75
WGS
GeneDx Holdings Corp.
141.72-8.89